What are the indications for Deucravacitinib?

Deucravacitinib is an oral small molecule targeted inhibitor of tyrosine kinase 2 (TYK2). It is mainly approved for the treatment of adult patients with moderate to severe plaque psoriasis (Plaque Psoriasis), especially those who are not suitable for traditional topical treatment, phototherapy or require systemic treatment. Its precise mechanism of action marks a new stage of psoriasis treatment that is more targeted and personalized.

Plaque psoriasis is a chronic, autoimmune-mediated inflammatory skin disease, clinically characterized by erythema, scales, and itching. Traditional treatments include topical hormones, phototherapy, methotrexate, cyclosporine, and biological agents. However, long-term treatment is often plagued by problems such as drug resistance, adverse reactions, or poor compliance.

Deuterated colexitinib is a new type of oral TYK2 inhibitor. By inhibiting the signal transduction of IL-23, IL-12 and type I interferon, it can significantly reduce the interference with the body's extensive immune function while maintaining efficacy, thereby achieving better safety.

Its main indications are patients with moderate to severe plaque psoriasis who have failed to respond to previous local therapies or have repeatedly relapsed, and whose lesions are widely covered. This group of people often face clinical problems such as long-term treatment needs, protracted disease course, and limited quality of life. The use of deuterated colexitinib can significantly improve the lesion area, itching degree, and skin healing speed. Especially among patients with psychological burden or underlying diseases such as metabolic syndrome, its oral, once-daily medication method can significantly improve compliance.

In addition to psoriasis, there are currently studies exploring its potential indications in other immune-related diseases such as psoriatic arthritis, lupus erythematosus or ulcerative colitis. Although it has not yet been officially approved, judging from its mechanism of action, these diseases also involve abnormalities in the TYK2 signaling pathway, which provides a theoretical basis for its expansion of clinical use.

Reference materials:https://go.drugbank.com/drugs/DB16650